BioCentury
ARTICLE | Company News

Bristol-Myers, Duke institute in research partnership

February 29, 2012 2:07 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) and the Duke Translational Medicine Institute will co-develop and co-implement the protocol for a Phase II trial of the pharma's BMS-986202 (formerly AM152) for idiopathic pulmonary fibrosis (IPF). The trial is slated to begin late this year. The partners also will conduct biomarker validation studies. BMS gained rights to the oral lysophosphatidic acid receptor 1 ( LPA1) antagonist through its acquisition of Amira Pharmaceuticals Inc. last year (see BioCentury, Aug. 1, 2011). ...